順誠(00531.HK)年度扭虧為盈至2715.8萬美元 每股派0.02港元
格隆匯3月24日丨順誠(00531.HK)公佈,截至2021年12月31日止年度,實現收益4.88億美元,同比增長22.77%;毛利1.29億美元,同比增長34.62%;母公司擁有人應占盈利2715.8萬美元,上年度為虧損1400.7萬美元;基本每股盈利0.87美仙,末期股息每股0.02港元。
公吿稱,業績扭虧為盈主要是由於集團於該年度將位於中國的經營場址由自用物業更改為租賃物業用途,使可回收金額增加,因此錄得減值的一次性非現金撥回約700萬美元所致。此外,年內溢利乃歸因於銷售增長、利潤改善及營運開支減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.